首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis.
【24h】

Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis.

机译:对熊去氧胆酸的生化反应可预测日本原发性胆汁性肝硬化患者的长期预后。

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: There is an ongoing need for predictors of long-term outcomes for patients with primary biliary cirrhosis (PBC). Biochemical response to ursodeoxycholic acid (UDCA) has been introduced to predict development of symptoms by our group (Ehime criteria) and to predict long-term outcomes in Western countries (Paris, Barcelona and Rotterdam criteria). The aim of this study was to evaluate whether these criteria are also useful to predict long-term outcomes in Japanese patients with PBC. Methods: A retrospective chart review was conducted for 227 Japanese patients with PBC. Patients taking UDCA with an observation period of more than 6 months were included in the study. Data collection included demographics, biochemical and serological markers, and histological stage. Four different criteria regarding biochemical response to UDCA were compared and evaluated. Results: In total, 138 patients met the inclusion criteria and underwent analysis. Using the Ehime criteria, the transplant-free survival rate was significantly higher in responders than in non-responders (P = 0.010). The Paris criteria also predicted long-term outcomes in our population (P = 0.003), whereas the Barcelona and Rotterdam criteria showed no such association (P = 0.282 and P = 0.553, respectively). Conclusion: Good biochemical response to UDCA according to the Ehime and Paris criteria is associated with long-term outcome in Japanese patients with PBC and allows identification of non-responders who may benefit from further trials. Finally, Ehime criteria should be validated in a different patient cohort.
机译:目的:对于原发性胆汁性肝硬化(PBC)患者的长期预后指标存在持续的需求。已引入对熊去氧胆酸(UDCA)的生化反应来预测我们小组的症状发展(爱媛标准),并预测西方国家的长期结果(巴黎,巴塞罗那和鹿特丹标准)。这项研究的目的是评估这些标准是否也有助于预测日本PBC患者的长期结局。方法:对227例日本PBC患者进行回顾性图表回顾。该研究包括观察期超过6个月的服用UDCA的患者。数据收集包括人口统计学,生化和血清学标志物以及组织学阶段。比较和评估了关于对UDCA的生化反应的四个不同标准。结果:总共138例符合纳入标准并接受了分析。使用爱媛标准,有反应者的无移植生存率显着高于无反应者(P = 0.010)。巴黎标准还预测了我们人口的长期结果(P = 0.003),而巴塞罗那和鹿特丹标准没有显示出这种关联(分别为P = 0.282和P = 0.553)。结论:根据爱媛县和巴黎标准,对UDCA的良好生化反应与日本PBC患者的长期预后相关,并可以鉴定出可能从进一步试验中受益的无反应者。最后,爱媛标准应该在不同的患者队列中得到验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号